dose site and the vitreous humor samples from the high dose group had the next highest
concentrations at 2.0x10
5
and 3.9x10
4
copies, respectively. Aside from the dose site, the levels of
GT005 across the biodistribution samples were comparable between the low and high dose groups.
Spleen samples demonstrated sporadic and relatively low concentrations of GT005, while the
heart, kidney, liver, lung, ovary, and testes samples all tested below the assay limit of detection
(BLOD), indicating a lack of sustained and systemic vector spreading or biodistribution 183 days
after a single subretinal injection of GT005.
Numerous integration studies have however been performed evaluating the integration frequency,
as well as the integration sites, of rAAV vectors. Integration has been shown to occur preferentially
into RefSeq genes, CpG islands, near transcription start regions, into rRNA gene repeats, and in
some studies, DNA palindromes [Inagaki et al., 2007; Miller et al., 2004; Nakai et al., 1999; Nakai
et al., 2003; Nakai et al., 2005]. It was also suggested that AAV vectors integrate at pre-existing
chromosome breaks, rather than causing breaks themselves [Miller et al., 2004]. Based on current
knowledge, GT005 is concluded to present a similar risk with respect to genomic integration when
compared to wild-type AAV.
HOST IMMUNE RESPONSES TO GT005
The host immune response to GT005 is not expected to be different from wild-type AAV2, as
reviewed in Daya and Berns (2008). Interim clinical immunogenicity data on GT005, as of
December 2020, show that antibodies to CFI have not been detected in any subject and at any time
point. One subject had a transiently positive anti-AAV2 T cell response, which was absent at Week
24 post-treatment. No positive T cell response to AAV2 was detected for all other patients. Almost
no innate immune response is seen in AAV infection and the host defence mechanism at the
adaptive level is primarily made up of a humoral response [Xiao et al., 1996]. Pre-existing
antibodies, due to prior AAV infections, account for the observed humoral response in patients
receiving rAAV vectors (reviewed in Ertl and High, 2017). The cell-mediated response functions by
eliminating transduced cells through cytotoxic T cells. Cell-mediated responses to AAV vectors
have been documented, but may be dependent on several factors, including the vector dose, route
of administration, and prior exposure to the AAV serotype [Ertl and High, 2017]. Subjects treated
with GT005 will therefore be given prophylactic corticosteroids around the time of the subretinal
injection of the GMO to treat potential immune reactions.
Doses used in ophthalmo
logy are considerably smaller than other applications such as in
haematology, where doses in the range of E13 vg/kg are used and, when compared to systemic
delivery of AAVs targeting organs such as the liver, the eye represents a site of immune privilege.
Nevertheless, intraocular inflammation following subretinal delivery of AAV gene therapy in
humans has been recorded, however it is usually not clinically significant and is readily controllable.
In the Phase II study, the highest proposed dose of GT005 is 2E11 vg and as mentioned above
subjects treated with GT005 will be given prophylactic corticosteroids around the time of the
subretinal injection of the GMO to treat potential immune reactions.
Immunological reactions are nevertheless rare following AAV injection into the subretinal space.
AAVs elicit a minimal immune response and allow for stable and long-term transgene expression
in different retinal cells, including photoreceptors, retinal pigment epithelium (RPE) cells, ganglion
and Muller cells [Vandenberghe and Auricchio, 2012]. Exposed individuals could seroconvert to an
AAV2-positive titre. There has been no indication from any of the previous AAV human trials that